Pizotifen (malate) Reference: 20765-100 A triptan with high affinity for serotonin and dopamine receptors (Kis = 7.94 and 2.4 nM for 5-HT2C and D2, respectively)
Pizotifen (malate) Reference: 20765-250 A triptan with high affinity for serotonin and dopamine receptors (Kis = 7.94 and 2.4 nM for 5-HT2C and D2, respectively)
Pizotifen (malate) Reference: 20765-500 A triptan with high affinity for serotonin and dopamine receptors (Kis = 7.94 and 2.4 nM for 5-HT2C and D2, respectively)
Piperacillin (sodium salt) Reference: 20766-1 A broad-spectrum β-lactam antibiotic; active against Gram-negative and Gram-positive bacteria, including Enterococcus species, E. coli, and P. mirabilis (MIC50s = 0.5-2 µg/ml) as well as gentamicin-susceptible and -resistant strains of P. aeruginosa (MIC50s = 8 and 125 µg/ml, respectively); active against P. aeruginosa 46220 when used alone or in combination with tazobactam (ED50s = 1.58 and 1.34 mg/animal, respectively) in a mouse model of systemic infection; less active against P. aeruginosa 46220 DR-2 when used alone than when used in combination with tazobactam (ED50s = >20 and 4.39 mg/animal, respectively) in a mouse model of systemic infection
Piperacillin (sodium salt) Reference: 20766-10 A broad-spectrum β-lactam antibiotic; active against Gram-negative and Gram-positive bacteria, including Enterococcus species, E. coli, and P. mirabilis (MIC50s = 0.5-2 µg/ml) as well as gentamicin-susceptible and -resistant strains of P. aeruginosa (MIC50s = 8 and 125 µg/ml, respectively); active against P. aeruginosa 46220 when used alone or in combination with tazobactam (ED50s = 1.58 and 1.34 mg/animal, respectively) in a mouse model of systemic infection; less active against P. aeruginosa 46220 DR-2 when used alone than when used in combination with tazobactam (ED50s = >20 and 4.39 mg/animal, respectively) in a mouse model of systemic infection
Piperacillin (sodium salt) Reference: 20766-5 A broad-spectrum β-lactam antibiotic; active against Gram-negative and Gram-positive bacteria, including Enterococcus species, E. coli, and P. mirabilis (MIC50s = 0.5-2 µg/ml) as well as gentamicin-susceptible and -resistant strains of P. aeruginosa (MIC50s = 8 and 125 µg/ml, respectively); active against P. aeruginosa 46220 when used alone or in combination with tazobactam (ED50s = 1.58 and 1.34 mg/animal, respectively) in a mouse model of systemic infection; less active against P. aeruginosa 46220 DR-2 when used alone than when used in combination with tazobactam (ED50s = >20 and 4.39 mg/animal, respectively) in a mouse model of systemic infection